earnings
confidence high
sentiment positive
materiality 0.70
Vyome reports Q3 cash $5.7M; VT-1953 Phase 2 interim hits primary endpoint
Vyome Holdings, Inc
2025-Q3 EPS reported
-$10.00
revenue$283,163
- VT-1953 Phase 2 interim data: statistically significant malodor reduction (p<0.001); pain and QoL improved; safety profile excellent.
- Cash, equivalents & short-term investments $5.7 million; expected runway through end of 2026 inclusive of clinical trials.
- Net loss primarily from one-time merger/financing non-cash charges; company is pre-revenue clinical stage.
- Clean capital structure: 5,556,295 shares outstanding, no preferred stock, no warrants or convertible notes.
- Acquired MIT startup Oculo to launch AI strategy; hired new CTO and SVP of Clinical Development with Big Pharma backgrounds.